Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Alpha-enolase (EC 4.2.1.11) (2-phospho-D-glycerate hydro-lyase) (C-myc promoter-binding protein) (Enolase 1) (MBP-1) (MPB-1) (Non-neural enolase) (NNE) (Phosphopyruvate hydratase) (Plasminogen-binding protein)

 ENOA_HUMAN              Reviewed;         434 AA.
P06733; B2RD59; P22712; Q16704; Q4TUS4; Q53FT9; Q53HR3; Q658M5;
Q6GMP2; Q71V37; Q7Z3V6; Q8WU71; Q96GV1; Q9BT62; Q9UCH6; Q9UM55;
01-JAN-1988, integrated into UniProtKB/Swiss-Prot.
23-JAN-2007, sequence version 2.
22-NOV-2017, entry version 218.
RecName: Full=Alpha-enolase;
EC=4.2.1.11;
AltName: Full=2-phospho-D-glycerate hydro-lyase;
AltName: Full=C-myc promoter-binding protein;
AltName: Full=Enolase 1;
AltName: Full=MBP-1;
AltName: Full=MPB-1;
AltName: Full=Non-neural enolase;
Short=NNE;
AltName: Full=Phosphopyruvate hydratase;
AltName: Full=Plasminogen-binding protein;
Name=ENO1; Synonyms=ENO1L1, MBPB1, MPB1;
Homo sapiens (Human).
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
Catarrhini; Hominidae; Homo.
NCBI_TaxID=9606;
[1]
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ALPHA-ENOLASE).
PubMed=3529090; DOI=10.1073/pnas.83.18.6741;
Giallongo A., Feo S., Moore R., Croce C.M., Showe L.C.;
"Molecular cloning and nucleotide sequence of a full-length cDNA for
human alpha enolase.";
Proc. Natl. Acad. Sci. U.S.A. 83:6741-6745(1986).
[2]
NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM ALPHA-ENOLASE).
TISSUE=T-cell;
PubMed=2373081; DOI=10.1111/j.1432-1033.1990.tb15611.x;
Giallongo A., Oliva D., Cali L., Barba G., Barbieri G., Feo S.;
"Structure of the human gene for alpha-enolase.";
Eur. J. Biochem. 190:567-573(1990).
[3]
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM MBP-1), AND FUNCTION.
TISSUE=Cervix carcinoma;
PubMed=2005901; DOI=10.1128/MCB.11.4.2154;
Ray R., Miller D.M.;
"Cloning and characterization of a human c-myc promoter-binding
protein.";
Mol. Cell. Biol. 11:2154-2161(1991).
[4]
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ALPHA-ENOLASE), AND MARKER FOR
ENDOMETRIOSIS.
TISSUE=Endometrium;
PubMed=8824716; DOI=10.1016/S0896-8411(95)80027-1;
Walter M., Berg H., Leidenberger F.A., Schweppe K.W., Northemann W.;
"Autoreactive epitopes within the human alpha-enolase and their
recognition by sera from patients with endometriosis.";
J. Autoimmun. 8:931-945(1995).
[5]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA-ENOLASE).
Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
Phelan M., Farmer A.;
"Cloning of human full-length CDSs in BD Creator(TM) system donor
vector.";
Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
[6]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA-ENOLASE).
TISSUE=Umbilical cord blood;
PubMed=14702039; DOI=10.1038/ng1285;
Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
"Complete sequencing and characterization of 21,243 full-length human
cDNAs.";
Nat. Genet. 36:40-45(2004).
[7]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA-ENOLASE).
TISSUE=Adipose tissue, and Kidney proximal tubule;
Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
Tanaka A., Yokoyama S.;
Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
[8]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA-ENOLASE).
TISSUE=Retina, and Stomach;
PubMed=17974005; DOI=10.1186/1471-2164-8-399;
Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
"The full-ORF clone resource of the German cDNA consortium.";
BMC Genomics 8:399-399(2007).
[9]
NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-177.
NIEHS SNPs program;
Submitted (MAY-2005) to the EMBL/GenBank/DDBJ databases.
[10]
NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
PubMed=16710414; DOI=10.1038/nature04727;
Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
Beck S., Rogers J., Bentley D.R.;
"The DNA sequence and biological annotation of human chromosome 1.";
Nature 441:315-321(2006).
[11]
NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
Venter J.C.;
Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
[12]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA-ENOLASE).
TISSUE=Brain, Eye, Lung, Ovary, Placenta, and Skin;
PubMed=15489334; DOI=10.1101/gr.2596504;
The MGC Project Team;
"The status, quality, and expansion of the NIH full-length cDNA
project: the Mammalian Gene Collection (MGC).";
Genome Res. 14:2121-2127(2004).
[13]
PROTEIN SEQUENCE OF 2-9 (ISOFORM ALPHA-ENOLASE).
TISSUE=Colon carcinoma;
PubMed=9150948; DOI=10.1002/elps.1150180344;
Ji H., Reid G.E., Moritz R.L., Eddes J.S., Burgess A.W., Simpson R.J.;
"A two-dimensional gel database of human colon carcinoma proteins.";
Electrophoresis 18:605-613(1997).
[14]
PROTEIN SEQUENCE OF 2-28; 65-80; 121-162; 234-253; 270-281; 331-394
AND 407-420, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT SER-2,
AND IDENTIFICATION BY MASS SPECTROMETRY.
TISSUE=Colon carcinoma;
Bienvenut W.V., Lilla S., Zebisch A., Kolch W.;
Submitted (MAR-2009) to UniProtKB.
[15]
PROTEIN SEQUENCE OF 16-28; 33-50; 93-103; 106-120; 163-179; 184-193;
203-221; 240-253; 257-262; 270-281; 286-326; 336-394 AND 407-412, AND
IDENTIFICATION BY MASS SPECTROMETRY.
TISSUE=Brain, Cajal-Retzius cell, and Fetal brain cortex;
Lubec G., Vishwanath V., Chen W.-Q., Sun Y.;
Submitted (DEC-2008) to UniProtKB.
[16]
NUCLEOTIDE SEQUENCE [MRNA] OF 166-434.
PubMed=9653645; DOI=10.1006/geno.1997.5186;
Onyango P., Lubyova B., Gardellin P., Kurzbauer R., Weith A.;
"Molecular cloning and expression analysis of five novel genes in
chromosome 1p36.";
Genomics 50:187-198(1998).
[17]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 171-434.
TISSUE=Brain;
PubMed=9110174;
Yu W., Andersson B., Worley K.C., Muzny D.M., Ding Y., Liu W.,
Ricafrente J.Y., Wentland M.A., Lennon G., Gibbs R.A.;
"Large-scale concatenation cDNA sequencing.";
Genome Res. 7:353-358(1997).
[18]
PROTEIN SEQUENCE OF 203-228, FUNCTION, CATALYTIC ACTIVITY, AND
BIOPHYSICOCHEMICAL PROPERTIES.
TISSUE=Lymphoma;
PubMed=1369209; DOI=10.1007/BF00570890;
Sugahara T., Nakajima H., Shirahata S., Murakami H.;
"Purification and characterization of immunoglobulin production
stimulating factor-II beta derived from Namalwa cells.";
Cytotechnology 10:137-146(1992).
[19]
PROTEIN SEQUENCE OF 270-281 AND 307-321, AND INDUCTION IN DIFFUSE
LARGE CELL LYMPHOMA.
PubMed=7787969;
Mohamad R.M., Hamdan M.Y., Maki A., Al-Katib A.;
"Induced expression of alpha-enolase in differentiated diffuse large
cell lymphoma.";
Enzyme Protein 48:37-44(1994).
[20]
FUNCTION OF MBP1, IDENTIFICATION OF REPRESSOR DOMAINS, AND MUTAGENESIS
OF LEU-384 AND LEU-388.
PubMed=10082554; DOI=10.1128/MCB.19.4.2880;
Ghosh A.K., Steele R., Ray R.B.;
"Functional domains of c-myc promoter binding protein 1 involved in
transcriptional repression and cell growth regulation.";
Mol. Cell. Biol. 19:2880-2886(1999).
[21]
FUNCTION AS A C-MYC TRANSCRIPTIONAL REPRESSOR, AND SUBCELLULAR
LOCATION.
PubMed=10802057; DOI=10.1016/S0014-5793(00)01494-0;
Feo S., Arcuri D., Piddini E., Passantino R., Giallongo A.;
"ENO1 gene product binds to the c-myc promoter and acts as a
transcriptional repressor: relationship with Myc promoter-binding
protein 1 (MBP-1).";
FEBS Lett. 473:47-52(2000).
[22]
FUNCTION IN PLASMINOGEN ACTIVATION.
PubMed=12666133; DOI=10.1002/ajh.10299;
Lopez-Alemany R., Longstaff C., Hawley S., Mirshahi M., Fabregas P.,
Jardi M., Merton E., Miles L.A., Felez J.;
"Inhibition of cell surface mediated plasminogen activation by a
monoclonal antibody against alpha-enolase.";
Am. J. Hematol. 72:234-242(2003).
[23]
INTERACTION WITH PLG.
PubMed=9308760;
Arza B., Felez J., Lopez-Alemany R., Miles L.A., Munoz-Canoves P.;
"Identification of an epitope of alpha-enolase (a candidate
plasminogen receptor) by phage display.";
Thromb. Haemost. 78:1097-1103(1997).
[24]
EPITOPE MAPPING, AND ASSOCIATION WITH CAR.
PubMed=9878089; DOI=10.1006/jaut.1998.0239;
Adamus G., Amundson D., Seigel G.M., Machnicki M.;
"Anti-enolase-alpha autoantibodies in cancer-associated retinopathy:
epitope mapping and cytotoxicity on retinal cells.";
J. Autoimmun. 11:671-677(1998).
[25]
IDENTIFICATION OF MBP1 AS AN ALPHA-ENOLASE ALTERNATIVE INITIATION
PRODUCT, AND MUTAGENESIS OF MET-94 AND MET-97.
PubMed=10681589; DOI=10.1074/jbc.275.8.5958;
Subramanian A., Miller D.M.;
"Structural analysis of alpha-enolase. Mapping the functional domains
involved in down-regulation of the c-myc protooncogene.";
J. Biol. Chem. 275:5958-5965(2000).
[26]
REVIEW.
PubMed=11497239; DOI=10.1007/PL00000910;
Pancholi V.;
"Multifunctional alpha-enolase: its role in diseases.";
Cell. Mol. Life Sci. 58:902-920(2001).
[27]
INTERACTION WITH TRAPPC2B (ISOFORM MBP-1).
PubMed=11134351; DOI=10.1128/MCB.21.2.655-662.2001;
Ghosh A.K., Majumder M., Steele R., White R.A., Ray R.B.;
"A novel 16-kilodalton cellular protein physically interacts with and
antagonizes the functional activity of c-myc promoter-binding protein
1.";
Mol. Cell. Biol. 21:655-662(2001).
[28]
IDENTIFICATION AS AN AUTOANTIGEN IN HASHIMOTO ENCEPHALOPATHY.
PubMed=12297304; DOI=10.1016/S0014-5793(02)03307-0;
Ochi H., Horiuchi I., Araki N., Toda T., Araki T., Sato K., Murai H.,
Osoegawa M., Yamada T., Okamura K., Ogino T., Mizumoto K.,
Yamashita H., Saya H., Kira J.;
"Proteomic analysis of human brain identifies alpha-enolase as a novel
autoantigen in Hashimoto's encephalopathy.";
FEBS Lett. 528:197-202(2002).
[29]
ISGYLATION.
PubMed=16139798; DOI=10.1016/j.bbrc.2005.08.132;
Giannakopoulos N.V., Luo J.K., Papov V., Zou W., Lenschow D.J.,
Jacobs B.S., Borden E.C., Li J., Virgin H.W., Zhang D.E.;
"Proteomic identification of proteins conjugated to ISG15 in mouse and
human cells.";
Biochem. Biophys. Res. Commun. 336:496-506(2005).
[30]
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-44 AND TYR-287, AND
IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
PubMed=15592455; DOI=10.1038/nbt1046;
Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
Zha X.-M., Polakiewicz R.D., Comb M.J.;
"Immunoaffinity profiling of tyrosine phosphorylation in cancer
cells.";
Nat. Biotechnol. 23:94-101(2005).
[31]
INDUCTION, AND IDENTIFICATION BY MASS SPECTROMETRY.
PubMed=16548883; DOI=10.1111/j.1462-5822.2005.00644.x;
Leong W.F., Chow V.T.;
"Transcriptomic and proteomic analyses of rhabdomyosarcoma cells
reveal differential cellular gene expression in response to
enterovirus 71 infection.";
Cell. Microbiol. 8:565-580(2006).
[32]
ISGYLATION.
PubMed=16815975; DOI=10.1073/pnas.0600397103;
Wong J.J., Pung Y.F., Sze N.S., Chin K.C.;
"HERC5 is an IFN-induced HECT-type E3 protein ligase that mediates
type I IFN-induced ISGylation of protein targets.";
Proc. Natl. Acad. Sci. U.S.A. 103:10735-10740(2006).
[33]
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-254 AND SER-263, AND
IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
TISSUE=Cervix carcinoma;
PubMed=18669648; DOI=10.1073/pnas.0805139105;
Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
Elledge S.J., Gygi S.P.;
"A quantitative atlas of mitotic phosphorylation.";
Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
[34]
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-272, AND IDENTIFICATION
BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
TISSUE=Leukemic T-cell;
PubMed=19690332; DOI=10.1126/scisignal.2000007;
Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
Rodionov V., Han D.K.;
"Quantitative phosphoproteomic analysis of T cell receptor signaling
reveals system-wide modulation of protein-protein interactions.";
Sci. Signal. 2:RA46-RA46(2009).
[35]
ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-5; LYS-64; LYS-71; LYS-89;
LYS-126; LYS-193; LYS-199; LYS-228; LYS-233; LYS-256; LYS-281; LYS-285
AND LYS-420, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
ANALYSIS].
PubMed=19608861; DOI=10.1126/science.1175371;
Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
Walther T.C., Olsen J.V., Mann M.;
"Lysine acetylation targets protein complexes and co-regulates major
cellular functions.";
Science 325:834-840(2009).
[36]
IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
TISSUE=Cervix carcinoma;
PubMed=20068231; DOI=10.1126/scisignal.2000475;
Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
Mann M.;
"Quantitative phosphoproteomics reveals widespread full
phosphorylation site occupancy during mitosis.";
Sci. Signal. 3:RA3-RA3(2010).
[37]
IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
PubMed=21269460; DOI=10.1186/1752-0509-5-17;
Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
"Initial characterization of the human central proteome.";
BMC Syst. Biol. 5:17-17(2011).
[38]
MALONYLATION AT LYS-233 AND LYS-420.
PubMed=21908771; DOI=10.1074/mcp.M111.012658;
Peng C., Lu Z., Xie Z., Cheng Z., Chen Y., Tan M., Luo H., Zhang Y.,
He W., Yang K., Zwaans B.M., Tishkoff D., Ho L., Lombard D., He T.C.,
Dai J., Verdin E., Ye Y., Zhao Y.;
"The first identification of lysine malonylation substrates and its
regulatory enzyme.";
Mol. Cell. Proteomics 10:M111.012658.01-M111.012658.12(2011).
[39]
IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
PubMed=22905912; DOI=10.1021/pr300539b;
Rosenow A., Noben J.P., Jocken J., Kallendrusch S.,
Fischer-Posovszky P., Mariman E.C., Renes J.;
"Resveratrol-induced changes of the human adipocyte secretion
profile.";
J. Proteome Res. 11:4733-4743(2012).
[40]
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-27; SER-254; SER-263 AND
SER-272, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
ANALYSIS].
TISSUE=Cervix carcinoma, and Erythroleukemia;
PubMed=23186163; DOI=10.1021/pr300630k;
Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
Mohammed S.;
"Toward a comprehensive characterization of a human cancer cell
phosphoproteome.";
J. Proteome Res. 12:260-271(2013).
[41]
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-263 AND SER-291, AND
IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
TISSUE=Liver;
PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
Wang L., Ye M., Zou H.;
"An enzyme assisted RP-RPLC approach for in-depth analysis of human
liver phosphoproteome.";
J. Proteomics 96:253-262(2014).
[42]
ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
SPECTROMETRY [LARGE SCALE ANALYSIS].
PubMed=25944712; DOI=10.1002/pmic.201400617;
Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
"N-terminome analysis of the human mitochondrial proteome.";
Proteomics 15:2519-2524(2015).
[43]
SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-202, AND IDENTIFICATION BY
MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
PubMed=28112733; DOI=10.1038/nsmb.3366;
Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
Nielsen M.L.;
"Site-specific mapping of the human SUMO proteome reveals co-
modification with phosphorylation.";
Nat. Struct. Mol. Biol. 24:325-336(2017).
[44]
X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 2-434, SUBUNIT, COFACTOR, AND
METAL-BINDING SITES.
PubMed=18560153; DOI=10.1107/S0907444908008561;
Kang H.J., Jung S.K., Kim S.J., Chung S.J.;
"Structure of human alpha-enolase (hENO1), a multifunctional
glycolytic enzyme.";
Acta Crystallogr. D 64:651-657(2008).
-!- FUNCTION: Multifunctional enzyme that, as well as its role in
glycolysis, plays a part in various processes such as growth
control, hypoxia tolerance and allergic responses. May also
function in the intravascular and pericellular fibrinolytic system
due to its ability to serve as a receptor and activator of
plasminogen on the cell surface of several cell-types such as
leukocytes and neurons. Stimulates immunoglobulin production.
-!- FUNCTION: MBP1 binds to the myc promoter and acts as a
transcriptional repressor. May be a tumor suppressor.
-!- CATALYTIC ACTIVITY: 2-phospho-D-glycerate = phosphoenolpyruvate +
H(2)O. {ECO:0000269|PubMed:1369209}.
-!- COFACTOR:
Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
Evidence={ECO:0000269|PubMed:18560153};
Note=Binds two Mg(2+) per subunit. Required for catalysis and for
stabilizing the dimer. {ECO:0000269|PubMed:18560153};
-!- BIOPHYSICOCHEMICAL PROPERTIES:
pH dependence:
Enolase activity is lost above pH 9.0. Immunoglobulin production
stimulating activity is retained at pH 13.0.
{ECO:0000269|PubMed:1369209};
-!- PATHWAY: Carbohydrate degradation; glycolysis; pyruvate from D-
glyceraldehyde 3-phosphate: step 4/5.
-!- SUBUNIT: Mammalian enolase is composed of 3 isozyme subunits,
alpha, beta and gamma, which can form homodimers or heterodimers
which are cell-type and development-specific (PubMed:18560153).
ENO1 interacts with PLG in the neuronal plasma membrane and
promotes its activation. The C-terminal lysine is required for
this binding (PubMed:9308760). Isoform MBP-1 interacts with
TRAPPC2B (PubMed:11134351). Interacts with ENO4 and PGAM2 (By
similarity). {ECO:0000250|UniProtKB:P17182,
ECO:0000269|PubMed:11134351, ECO:0000269|PubMed:18560153,
ECO:0000269|PubMed:9308760}.
-!- INTERACTION:
P22303:ACHE; NbExp=2; IntAct=EBI-353877, EBI-1637793;
Q60823:Akt2 (xeno); NbExp=2; IntAct=EBI-353877, EBI-400263;
P12004:PCNA; NbExp=3; IntAct=EBI-353877, EBI-358311;
Q8WZ42:TTN; NbExp=3; IntAct=EBI-353877, EBI-681210;
P63104:YWHAZ; NbExp=2; IntAct=EBI-353877, EBI-347088;
-!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:10802057}.
Cell membrane {ECO:0000269|PubMed:10802057}. Cytoplasm, myofibril,
sarcomere, M line {ECO:0000269|PubMed:10802057}. Note=Can
translocate to the plasma membrane in either the homodimeric
(alpha/alpha) or heterodimeric (alpha/gamma) form. ENO1 is
localized to the M line.
-!- SUBCELLULAR LOCATION: Isoform MBP-1: Nucleus.
-!- ALTERNATIVE PRODUCTS:
Event=Alternative initiation; Named isoforms=2;
Name=alpha-enolase;
IsoId=P06733-1; Sequence=Displayed;
Name=MBP-1;
IsoId=P06733-2; Sequence=VSP_018725;
Note=It is uncertain whether the alternative initiation site is
at Met-94 or at Met-97.;
-!- TISSUE SPECIFICITY: The alpha/alpha homodimer is expressed in
embryo and in most adult tissues. The alpha/beta heterodimer and
the beta/beta homodimer are found in striated muscle, and the
alpha/gamma heterodimer and the gamma/gamma homodimer in neurons.
-!- DEVELOPMENTAL STAGE: During ontogenesis, there is a transition
from the alpha/alpha homodimer to the alpha/beta heterodimer in
striated muscle cells, and to the alpha/gamma heterodimer in nerve
cells.
-!- INDUCTION: Induced in diffuse large cell lymphoma (DLCL) after
treatment with the natural biological agent, Bryo1. Up-regulated
in response to enterovirus 71 (EV71) infection (at protein level).
{ECO:0000269|PubMed:16548883, ECO:0000269|PubMed:7787969}.
-!- PTM: ISGylated. {ECO:0000269|PubMed:16139798,
ECO:0000269|PubMed:16815975}.
-!- MISCELLANEOUS: Used as a diagnostic marker for many tumors and, in
the heterodimeric form, alpha/gamma, as a marker for hypoxic brain
injury after cardiac arrest. Also marker for endometriosis.
Antibodies against alpha-enolase are present in sera from patients
with cancer-associated retinopathy syndrome (CAR), a progressive
blinding disease which occurs in the presence of systemic tumor
growth, primarily small-cell carcinoma of the lung and other
malignancies. Is identified as an autoantigen in Hashimoto
encephalopathy (HE) a rare autoimmune disease associated with
Hashimoto thyroiditis (HT). HT is a disorder in which destructive
processes overcome the potential capacity of thyroid replacement
leading to hypothyroidism.
-!- SIMILARITY: Belongs to the enolase family. {ECO:0000305}.
-!- SEQUENCE CAUTION:
Sequence=AAA35698.1; Type=Frameshift; Positions=Several; Evidence={ECO:0000305};
Sequence=AAA35698.1; Type=Miscellaneous discrepancy; Note=Sequencing errors.; Evidence={ECO:0000305};
-!- WEB RESOURCE: Name=NIEHS-SNPs;
URL="http://egp.gs.washington.edu/data/eno1/";
-!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
and Haematology;
URL="http://atlasgeneticsoncology.org/Genes/ENO1ID40453ch1p36.html";
-----------------------------------------------------------------------
Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
Distributed under the Creative Commons Attribution-NoDerivs License
-----------------------------------------------------------------------
EMBL; M14328; AAA52387.1; -; mRNA.
EMBL; X16288; CAA34360.1; -; Genomic_DNA.
EMBL; X16289; CAA34360.1; JOINED; Genomic_DNA.
EMBL; X16290; CAA34360.1; JOINED; Genomic_DNA.
EMBL; M55914; AAA35698.1; ALT_FRAME; mRNA.
EMBL; X84907; CAA59331.1; -; mRNA.
EMBL; BT007163; AAP35827.1; -; mRNA.
EMBL; AK315417; BAG37806.1; -; mRNA.
EMBL; AL833741; CAH56247.1; -; mRNA.
EMBL; BX537400; CAD97642.1; -; mRNA.
EMBL; AK222517; BAD96237.1; -; mRNA.
EMBL; AK223192; BAD96912.1; -; mRNA.
EMBL; DQ056744; AAY43128.1; -; Genomic_DNA.
EMBL; AL139415; CAC42425.1; -; Genomic_DNA.
EMBL; CH471130; EAW71604.1; -; Genomic_DNA.
EMBL; BC001810; AAH01810.1; -; mRNA.
EMBL; BC004325; AAH04325.1; -; mRNA.
EMBL; BC004458; AAH04458.1; -; mRNA.
EMBL; BC009218; AAH09218.2; -; mRNA.
EMBL; BC009912; AAH09912.1; -; mRNA.
EMBL; BC011130; AAH11130.1; -; mRNA.
EMBL; BC015641; AAH15641.1; -; mRNA.
EMBL; BC021166; AAH21166.2; -; mRNA.
EMBL; BC022545; AAH22545.1; -; mRNA.
EMBL; BC027725; AAH27725.1; -; mRNA.
EMBL; BC050642; AAH50642.1; -; mRNA.
EMBL; U88968; AAC39935.1; -; mRNA.
EMBL; AF035286; AAB88178.1; -; mRNA.
CCDS; CCDS97.1; -. [P06733-1]
PIR; A39579; A39579.
PIR; S11696; A29170.
RefSeq; NP_001188412.1; NM_001201483.1. [P06733-2]
RefSeq; NP_001419.1; NM_001428.3. [P06733-1]
UniGene; Hs.517145; -.
PDB; 2PSN; X-ray; 2.20 A; A/B/C/D=1-434.
PDB; 3B97; X-ray; 2.20 A; A/B/C/D=2-434.
PDB; 5JLZ; X-ray; 1.99 A; E/F=26-40.
PDB; 5LAX; X-ray; 2.60 A; E/F=26-40.
PDBsum; 2PSN; -.
PDBsum; 3B97; -.
PDBsum; 5JLZ; -.
PDBsum; 5LAX; -.
ProteinModelPortal; P06733; -.
SMR; P06733; -.
BioGrid; 108338; 290.
IntAct; P06733; 90.
MINT; MINT-155303; -.
STRING; 9606.ENSP00000234590; -.
BindingDB; P06733; -.
ChEMBL; CHEMBL3298; -.
iPTMnet; P06733; -.
PhosphoSitePlus; P06733; -.
SwissPalm; P06733; -.
BioMuta; ENO1; -.
DMDM; 119339; -.
DOSAC-COBS-2DPAGE; P06733; -.
OGP; P06733; -.
REPRODUCTION-2DPAGE; IPI00465248; -.
REPRODUCTION-2DPAGE; P06733; -.
SWISS-2DPAGE; P06733; -.
UCD-2DPAGE; P06733; -.
EPD; P06733; -.
MaxQB; P06733; -.
PaxDb; P06733; -.
PeptideAtlas; P06733; -.
PRIDE; P06733; -.
TopDownProteomics; P06733-1; -. [P06733-1]
TopDownProteomics; P06733-2; -. [P06733-2]
DNASU; 2023; -.
Ensembl; ENST00000234590; ENSP00000234590; ENSG00000074800. [P06733-1]
GeneID; 2023; -.
KEGG; hsa:2023; -.
UCSC; uc001apj.3; human. [P06733-1]
CTD; 2023; -.
DisGeNET; 2023; -.
EuPathDB; HostDB:ENSG00000074800.13; -.
GeneCards; ENO1; -.
HGNC; HGNC:3350; ENO1.
HPA; CAB018614; -.
HPA; CAB069394; -.
HPA; HPA068284; -.
MIM; 172430; gene.
neXtProt; NX_P06733; -.
OpenTargets; ENSG00000074800; -.
PharmGKB; PA27786; -.
eggNOG; KOG2670; Eukaryota.
eggNOG; COG0148; LUCA.
GeneTree; ENSGT00840000129817; -.
HOVERGEN; HBG000067; -.
InParanoid; P06733; -.
KO; K01689; -.
OMA; EFMIIPV; -.
OrthoDB; EOG091G07NH; -.
PhylomeDB; P06733; -.
TreeFam; TF300391; -.
BioCyc; MetaCyc:ENSG00000074800-MONOMER; -.
BRENDA; 4.2.1.11; 2681.
Reactome; R-HSA-70171; Glycolysis.
Reactome; R-HSA-70263; Gluconeogenesis.
SABIO-RK; P06733; -.
SIGNOR; P06733; -.
UniPathway; UPA00109; UER00187.
ChiTaRS; ENO1; human.
EvolutionaryTrace; P06733; -.
GeneWiki; Alpha-enolase; -.
GenomeRNAi; 2023; -.
PMAP-CutDB; P06733; -.
PRO; PR:P06733; -.
Proteomes; UP000005640; Chromosome 1.
Bgee; ENSG00000074800; -.
ExpressionAtlas; P06733; baseline and differential.
Genevisible; P06733; HS.
GO; GO:0099738; C:cell cortex region; IDA:CAFA.
GO; GO:0009986; C:cell surface; IDA:CAFA.
GO; GO:0005737; C:cytoplasm; IDA:LIFEdb.
GO; GO:0005829; C:cytosol; IDA:CAFA.
GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
GO; GO:0031430; C:M band; IEA:UniProtKB-SubCell.
GO; GO:0016020; C:membrane; IDA:UniProtKB.
GO; GO:0005634; C:nucleus; IDA:UniProtKB.
GO; GO:0000015; C:phosphopyruvate hydratase complex; IDA:CAFA.
GO; GO:0005886; C:plasma membrane; IDA:CAFA.
GO; GO:0045296; F:cadherin binding; IDA:BHF-UCL.
GO; GO:0051020; F:GTPase binding; IPI:UniProtKB.
GO; GO:0000287; F:magnesium ion binding; IEA:InterPro.
GO; GO:0004634; F:phosphopyruvate hydratase activity; IMP:CAFA.
GO; GO:0042803; F:protein homodimerization activity; IDA:CAFA.
GO; GO:0003723; F:RNA binding; IDA:UniProtKB.
GO; GO:0000977; F:RNA polymerase II regulatory region sequence-specific DNA binding; IDA:NTNU_SB.
GO; GO:0001078; F:transcriptional repressor activity, RNA polymerase II core promoter proximal region sequence-specific binding; IDA:CAFA.
GO; GO:0001227; F:transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding; IDA:NTNU_SB.
GO; GO:0061621; P:canonical glycolysis; IMP:CAFA.
GO; GO:0006094; P:gluconeogenesis; TAS:Reactome.
GO; GO:0030308; P:negative regulation of cell growth; IDA:UniProtKB.
GO; GO:1903298; P:negative regulation of hypoxia-induced intrinsic apoptotic signaling pathway; IDA:CAFA.
GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:CAFA.
GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
GO; GO:2001171; P:positive regulation of ATP biosynthetic process; IDA:CAFA.
GO; GO:0045933; P:positive regulation of muscle contraction; IGI:CAFA.
GO; GO:0010756; P:positive regulation of plasminogen activation; IMP:CAFA.
GO; GO:0009615; P:response to virus; IEP:UniProtKB.
GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
CDD; cd03313; enolase; 1.
Gene3D; 3.20.20.120; -; 1.
Gene3D; 3.30.390.10; -; 1.
HAMAP; MF_00318; Enolase; 1.
InterPro; IPR000941; Enolase.
InterPro; IPR036849; Enolase-like_C.
InterPro; IPR029017; Enolase-like_N.
InterPro; IPR034390; Enolase-like_superfamily.
InterPro; IPR020810; Enolase_C.
InterPro; IPR020809; Enolase_CS.
InterPro; IPR020811; Enolase_N.
PANTHER; PTHR11902; PTHR11902; 1.
Pfam; PF00113; Enolase_C; 1.
Pfam; PF03952; Enolase_N; 1.
PIRSF; PIRSF001400; Enolase; 1.
PRINTS; PR00148; ENOLASE.
SFLD; SFLDG00178; enolase; 1.
SFLD; SFLDS00001; Enolase; 1.
SMART; SM01192; Enolase_C; 1.
SMART; SM01193; Enolase_N; 1.
SUPFAM; SSF51604; SSF51604; 1.
SUPFAM; SSF54826; SSF54826; 1.
TIGRFAMs; TIGR01060; eno; 1.
PROSITE; PS00164; ENOLASE; 1.
1: Evidence at protein level;
3D-structure; Acetylation; Alternative initiation; Cell membrane;
Complete proteome; Cytoplasm; Direct protein sequencing; DNA-binding;
Glycolysis; Isopeptide bond; Lyase; Magnesium; Membrane;
Metal-binding; Nucleus; Phosphoprotein; Plasminogen activation;
Polymorphism; Reference proteome; Repressor; Transcription;
Transcription regulation; Ubl conjugation.
INIT_MET 1 1 Removed. {ECO:0000244|PubMed:25944712,
ECO:0000269|Ref.14}.
CHAIN 2 434 Alpha-enolase.
/FTId=PRO_0000134097.
REGION 31 38 Epitope recognized by CAR and healthy
patient antibodies.
REGION 56 63 Epitope recognized by CAR antibodies.
REGION 97 237 Required for repression of c-myc promoter
activity.
REGION 370 373 Substrate binding. {ECO:0000250}.
REGION 405 434 Required for interaction with PLG.
{ECO:0000250}.
ACT_SITE 210 210 Proton donor. {ECO:0000250}.
ACT_SITE 343 343 Proton acceptor. {ECO:0000250}.
METAL 40 40 Magnesium 1.
METAL 245 245 Magnesium 2.
METAL 293 293 Magnesium 2.
METAL 318 318 Magnesium 2.
BINDING 158 158 Substrate. {ECO:0000250}.
BINDING 167 167 Substrate. {ECO:0000250}.
BINDING 293 293 Substrate. {ECO:0000250}.
BINDING 318 318 Substrate. {ECO:0000250}.
BINDING 394 394 Substrate. {ECO:0000250}.
MOD_RES 2 2 N-acetylserine.
{ECO:0000244|PubMed:25944712,
ECO:0000269|Ref.14}.
MOD_RES 5 5 N6-acetyllysine.
{ECO:0000244|PubMed:19608861}.
MOD_RES 27 27 Phosphoserine.
{ECO:0000244|PubMed:23186163}.
MOD_RES 44 44 Phosphotyrosine.
{ECO:0000244|PubMed:15592455}.
MOD_RES 60 60 N6-acetyllysine; alternate.
{ECO:0000250|UniProtKB:P17182}.
MOD_RES 60 60 N6-succinyllysine; alternate.
{ECO:0000250|UniProtKB:P17182}.
MOD_RES 64 64 N6-acetyllysine.
{ECO:0000244|PubMed:19608861}.
MOD_RES 71 71 N6-acetyllysine.
{ECO:0000244|PubMed:19608861}.
MOD_RES 89 89 N6-acetyllysine; alternate.
{ECO:0000244|PubMed:19608861}.
MOD_RES 89 89 N6-succinyllysine; alternate.
{ECO:0000250|UniProtKB:P17182}.
MOD_RES 92 92 N6-acetyllysine.
{ECO:0000250|UniProtKB:P17182}.
MOD_RES 126 126 N6-acetyllysine.
{ECO:0000244|PubMed:19608861}.
MOD_RES 193 193 N6-acetyllysine.
{ECO:0000244|PubMed:19608861}.
MOD_RES 199 199 N6-acetyllysine.
{ECO:0000244|PubMed:19608861}.
MOD_RES 202 202 N6-acetyllysine; alternate.
{ECO:0000250|UniProtKB:P17182}.
MOD_RES 228 228 N6-acetyllysine; alternate.
{ECO:0000244|PubMed:19608861}.
MOD_RES 228 228 N6-succinyllysine; alternate.
{ECO:0000250|UniProtKB:P17182}.
MOD_RES 233 233 N6-acetyllysine; alternate.
{ECO:0000244|PubMed:19608861}.
MOD_RES 233 233 N6-malonyllysine; alternate.
{ECO:0000269|PubMed:21908771}.
MOD_RES 254 254 Phosphoserine.
{ECO:0000244|PubMed:18669648,
ECO:0000244|PubMed:23186163}.
MOD_RES 256 256 N6-acetyllysine.
{ECO:0000244|PubMed:19608861}.
MOD_RES 263 263 Phosphoserine.
{ECO:0000244|PubMed:18669648,
ECO:0000244|PubMed:23186163,
ECO:0000244|PubMed:24275569}.
MOD_RES 272 272 Phosphoserine.
{ECO:0000244|PubMed:19690332,
ECO:0000244|PubMed:23186163}.
MOD_RES 281 281 N6-acetyllysine.
{ECO:0000244|PubMed:19608861}.
MOD_RES 285 285 N6-acetyllysine.
{ECO:0000244|PubMed:19608861}.
MOD_RES 287 287 Phosphotyrosine.
{ECO:0000244|PubMed:15592455}.
MOD_RES 291 291 Phosphoserine.
{ECO:0000244|PubMed:24275569}.
MOD_RES 335 335 N6-acetyllysine.
{ECO:0000250|UniProtKB:P17182}.
MOD_RES 343 343 N6-acetyllysine.
{ECO:0000250|UniProtKB:P17182}.
MOD_RES 406 406 N6-acetyllysine.
{ECO:0000250|UniProtKB:P17182}.
MOD_RES 420 420 N6-acetyllysine; alternate.
{ECO:0000244|PubMed:19608861}.
MOD_RES 420 420 N6-malonyllysine; alternate.
{ECO:0000269|PubMed:21908771}.
MOD_RES 420 420 N6-succinyllysine; alternate.
{ECO:0000250|UniProtKB:P17182}.
CROSSLNK 202 202 Glycyl lysine isopeptide (Lys-Gly)
(interchain with G-Cter in SUMO2);
alternate. {ECO:0000244|PubMed:28112733}.
VAR_SEQ 1 93 Missing (in isoform MBP-1).
{ECO:0000303|PubMed:2005901}.
/FTId=VSP_018725.
VARIANT 177 177 N -> K (in dbSNP:rs11544513).
{ECO:0000269|Ref.9}.
/FTId=VAR_025172.
VARIANT 325 325 P -> Q (in dbSNP:rs11544514).
/FTId=VAR_048936.
MUTAGEN 94 94 M->I: MBP1 protein production. No MBP1
protein production; when associated with
I-97. {ECO:0000269|PubMed:10681589}.
MUTAGEN 97 97 M->I: MBP1 protein production. No MBP1
protein production; when associated with
I-94. {ECO:0000269|PubMed:10681589}.
MUTAGEN 384 384 L->A: Loss of transcriptional repression
and cell growth inhibition; when
associated with A-388.
{ECO:0000269|PubMed:10082554}.
MUTAGEN 388 388 L->A: Loss of transcriptional repression
and cell growth inhibition; when
associated with A-384.
{ECO:0000269|PubMed:10082554}.
CONFLICT 55 55 T -> A (in Ref. 8; CAD97642).
{ECO:0000305}.
CONFLICT 78 78 V -> A (in Ref. 7; BAD96237).
{ECO:0000305}.
CONFLICT 187 187 E -> G (in Ref. 8; CAD97642).
{ECO:0000305}.
CONFLICT 199 199 K -> R (in Ref. 7; BAD96912).
{ECO:0000305}.
CONFLICT 252 252 F -> S (in Ref. 4; CAA59331).
{ECO:0000305}.
CONFLICT 310 310 S -> I (in Ref. 8; CAD97642).
{ECO:0000305}.
STRAND 5 12 {ECO:0000244|PDB:2PSN}.
STRAND 18 26 {ECO:0000244|PDB:2PSN}.
STRAND 29 34 {ECO:0000244|PDB:2PSN}.
HELIX 57 59 {ECO:0000244|PDB:2PSN}.
HELIX 63 71 {ECO:0000244|PDB:2PSN}.
HELIX 73 79 {ECO:0000244|PDB:2PSN}.
HELIX 87 98 {ECO:0000244|PDB:2PSN}.
TURN 104 106 {ECO:0000244|PDB:2PSN}.
HELIX 108 125 {ECO:0000244|PDB:2PSN}.
HELIX 130 138 {ECO:0000244|PDB:2PSN}.
STRAND 147 154 {ECO:0000244|PDB:2PSN}.
HELIX 156 158 {ECO:0000244|PDB:2PSN}.
STRAND 159 162 {ECO:0000244|PDB:2PSN}.
STRAND 167 171 {ECO:0000244|PDB:2PSN}.
HELIX 178 200 {ECO:0000244|PDB:2PSN}.
HELIX 202 204 {ECO:0000244|PDB:2PSN}.
HELIX 220 233 {ECO:0000244|PDB:2PSN}.
TURN 237 239 {ECO:0000244|PDB:2PSN}.
STRAND 241 245 {ECO:0000244|PDB:2PSN}.
HELIX 248 250 {ECO:0000244|PDB:2PSN}.
TURN 259 262 {ECO:0000244|PDB:2PSN}.
HELIX 267 269 {ECO:0000244|PDB:2PSN}.
HELIX 273 286 {ECO:0000244|PDB:2PSN}.
STRAND 289 293 {ECO:0000244|PDB:2PSN}.
HELIX 301 311 {ECO:0000244|PDB:2PSN}.
STRAND 313 318 {ECO:0000244|PDB:2PSN}.
TURN 319 323 {ECO:0000244|PDB:2PSN}.
HELIX 325 334 {ECO:0000244|PDB:2PSN}.
STRAND 338 342 {ECO:0000244|PDB:2PSN}.
HELIX 344 347 {ECO:0000244|PDB:2PSN}.
HELIX 350 362 {ECO:0000244|PDB:2PSN}.
STRAND 366 370 {ECO:0000244|PDB:2PSN}.
HELIX 380 387 {ECO:0000244|PDB:2PSN}.
STRAND 391 394 {ECO:0000244|PDB:2PSN}.
HELIX 401 417 {ECO:0000244|PDB:2PSN}.
HELIX 418 420 {ECO:0000244|PDB:2PSN}.
HELIX 425 427 {ECO:0000244|PDB:2PSN}.
SEQUENCE 434 AA; 47169 MW; A0ED663FCC15ADA5 CRC64;
MSILKIHARE IFDSRGNPTV EVDLFTSKGL FRAAVPSGAS TGIYEALELR DNDKTRYMGK
GVSKAVEHIN KTIAPALVSK KLNVTEQEKI DKLMIEMDGT ENKSKFGANA ILGVSLAVCK
AGAVEKGVPL YRHIADLAGN SEVILPVPAF NVINGGSHAG NKLAMQEFMI LPVGAANFRE
AMRIGAEVYH NLKNVIKEKY GKDATNVGDE GGFAPNILEN KEGLELLKTA IGKAGYTDKV
VIGMDVAASE FFRSGKYDLD FKSPDDPSRY ISPDQLADLY KSFIKDYPVV SIEDPFDQDD
WGAWQKFTAS AGIQVVGDDL TVTNPKRIAK AVNEKSCNCL LLKVNQIGSV TESLQACKLA
QANGWGVMVS HRSGETEDTF IADLVVGLCT GQIKTGAPCR SERLAKYNQL LRIEEELGSK
AKFAGRNFRN PLAK


Related products :

Catalog number Product name Quantity
15-288-22683 Alpha-enolase - EC 4.2.1.11; 2-phospho-D-glycerate hydro-lyase; Non-neural enolase; NNE; Enolase 1; Phosphopyruvate hydratase; C-myc promoter-binding protein; MBP-1; MPB-1; Plasminogen-binding protein 0.1 mg
18-003-42515 Alpha-enolase - EC 4.2.1.11; 2-phospho-D-glycerate hydro-lyase; Non-neural enolase; NNE; Enolase 1; Phosphopyruvate hydratase; C-myc promoter-binding protein; MBP-1; MPB-1; Plasminogen-binding protein 0.05 mg Aff Pur
18-003-42514 Alpha-enolase - EC 4.2.1.11; 2-phospho-D-glycerate hydro-lyase; Non-neural enolase; NNE; Enolase 1; Phosphopyruvate hydratase; C-myc promoter-binding protein; MBP-1; MPB-1; Plasminogen-binding protein 0.1 mg Protein A
18-003-42855 Alpha-enolase - EC 4.2.1.11; 2-phospho-D-glycerate hydro-lyase; Non-neural enolase; NNE; Enolase 1; Phosphopyruvate hydratase; C-myc promoter-binding protein; MBP-1; MPB-1; Plasminogen-binding protein 0.1 mg Protein A
15-288-22683 Alpha-enolase - EC 4.2.1.11; 2-phospho-D-glycerate hydro-lyase; Non-neural enolase; NNE; Enolase 1; Phosphopyruvate hydratase; C-myc promoter-binding protein; MBP-1; MPB-1; Plasminogen-binding protein 0.05 mg
U1449h CLIA 2-phospho-D-glycerate hydro-lyase,Alpha-enolase,C-myc promoter-binding protein,ENO1,ENO1L1,Enolase 1,Homo sapiens,Human,MBP-1,MBPB1,MPB1,MPB-1,NNE,Non-neural enolase,Phosphopyruvate hydratase,Pla 96T
E1449h ELISA 2-phospho-D-glycerate hydro-lyase,Alpha-enolase,C-myc promoter-binding protein,ENO1,ENO1L1,Enolase 1,Homo sapiens,Human,MBP-1,MBPB1,MPB1,MPB-1,NNE,Non-neural enolase,Phosphopyruvate hydratase,Pl 96T
E1449h ELISA kit 2-phospho-D-glycerate hydro-lyase,Alpha-enolase,C-myc promoter-binding protein,ENO1,ENO1L1,Enolase 1,Homo sapiens,Human,MBP-1,MBPB1,MPB1,MPB-1,NNE,Non-neural enolase,Phosphopyruvate hydrata 96T
E1449b ELISA 2-phospho-D-glycerate hydro-lyase,Alpha-enolase,Bos taurus,Bovine,ENO1,Enolase 1,HAP47,NNE,Non-neural enolase,Phosphopyruvate hydratase 96T
E1449b ELISA kit 2-phospho-D-glycerate hydro-lyase,Alpha-enolase,Bos taurus,Bovine,ENO1,Enolase 1,HAP47,NNE,Non-neural enolase,Phosphopyruvate hydratase 96T
U1449b CLIA 2-phospho-D-glycerate hydro-lyase,Alpha-enolase,Bos taurus,Bovine,ENO1,Enolase 1,HAP47,NNE,Non-neural enolase,Phosphopyruvate hydratase 96T
E0537m ELISA kit 2-phospho-D-glycerate hydro-lyase,Eno2,Eno-2,Enolase 2,Gamma-enolase,Mouse,Mus musculus,Neural enolase,Neuron-specific enolase,NSE 96T
U0537m CLIA 2-phospho-D-glycerate hydro-lyase,Eno2,Eno-2,Enolase 2,Gamma-enolase,Mouse,Mus musculus,Neural enolase,Neuron-specific enolase,NSE 96T
U0537r CLIA 2-phospho-D-glycerate hydro-lyase,Eno2,Eno-2,Enolase 2,Gamma-enolase,Neural enolase,Neuron-specific enolase,NSE,Rat,Rattus norvegicus 96T
E0537r ELISA kit 2-phospho-D-glycerate hydro-lyase,Eno2,Eno-2,Enolase 2,Gamma-enolase,Neural enolase,Neuron-specific enolase,NSE,Rat,Rattus norvegicus 96T
E0537r ELISA 2-phospho-D-glycerate hydro-lyase,Eno2,Eno-2,Enolase 2,Gamma-enolase,Neural enolase,Neuron-specific enolase,NSE,Rat,Rattus norvegicus 96T
E0537m ELISA 2-phospho-D-glycerate hydro-lyase,Eno2,Eno-2,Enolase 2,Gamma-enolase,Mouse,Mus musculus,Neural enolase,Neuron-specific enolase,NSE 96T
E1449m ELISA 2-phospho-D-glycerate hydro-lyase,Alpha-enolase,Eno1,Eno-1,Enolase 1,Mouse,Mus musculus,NNE,Non-neural enolase 96T
E1449r ELISA 2-phospho-D-glycerate hydro-lyase,Alpha-enolase,Eno1,Eno-1,Enolase 1,NNE,Non-neural enolase,Rat,Rattus norvegicus 96T
E1449m ELISA kit 2-phospho-D-glycerate hydro-lyase,Alpha-enolase,Eno1,Eno-1,Enolase 1,Mouse,Mus musculus,NNE,Non-neural enolase 96T
E1449r ELISA kit 2-phospho-D-glycerate hydro-lyase,Alpha-enolase,Eno1,Eno-1,Enolase 1,NNE,Non-neural enolase,Rat,Rattus norvegicus 96T
U1449r CLIA 2-phospho-D-glycerate hydro-lyase,Alpha-enolase,Eno1,Eno-1,Enolase 1,NNE,Non-neural enolase,Rat,Rattus norvegicus 96T
U1449m CLIA 2-phospho-D-glycerate hydro-lyase,Alpha-enolase,Eno1,Eno-1,Enolase 1,Mouse,Mus musculus,NNE,Non-neural enolase 96T
E0537h ELISA 2-phospho-D-glycerate hydro-lyase,ENO2,Enolase 2,Gamma-enolase,Homo sapiens,Human,Neural enolase,Neuron-specific enolase,NSE 96T
E0537h ELISA kit 2-phospho-D-glycerate hydro-lyase,ENO2,Enolase 2,Gamma-enolase,Homo sapiens,Human,Neural enolase,Neuron-specific enolase,NSE 96T


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur





GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017

BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG

france@gentaur.com | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur